Chief Medical Officer, Director of Clinical Research
Michigan Institute of Urology
Oakland University, William Beaumont School of Medicine
Dr. Hafron is the Chief Medical Officer and Director of Clinical Research at the Michigan Institute of Urology (MIU). Dr. Hafron is a Professor of Urology at the William Beaumont School of Medicine, Oakland University, Royal Oak, Michigan. He is experienced in all areas of adult urology, specializing in prostate, kidney, and bladder cancer.
Dr. Hafron received his Bachelor of Science degree from the University of Michigan and his Doctor of Medicine degree from Loyola University Chicago-Stritch School of Medicine. Dr. Hafron completed his General Surgery and Urology Residency at Albert Einstein College of Medicine, Montefiore Medical Center in New York City. He continued his training as a Fellow in Advanced Laparoscopic and Robotic Surgery at the Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, Ohio.
Dr. Hafron has published numerous peer reviewed journal articles on topics related to his expertise and presented his work at many national and international scientific meetings. He is the recipient of many clinical research awards. He is on the Editorial Board of the journal International Urology and Nephrology, Urologists in Cancer Care and Urology Times. He previously served on the Board of Directors of United Physicians Organization and currently serves on the Board of Directors for LUGPA. Dr. Hafron is board certified in the specialty of Urology by the American Board of Urology.
Approach to the Advanced Prostate Cancer Clinic for the Urologist
Saturday, September 23, 2023
1:00 PM – 2:00 PM CT
Disclosure(s): Amgen IncMeeting participant/lecturer: Meeting participant/lecturer (Ongoing); Astellas Pharma Inc;: Consultant (Ongoing); Bayer: Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Blue Earth Diagnostics: Consultant (Ongoing); Dendreon Pharmaceuticals LLC: Consultant (Ongoing), Meeting participant/lecturer Scientific Study/Trial (Ongoing); Eli Lilly and Company: Consultant (Ongoing); Immunis.AI: Consultant (Ongoing), Scientific Study/Trial (Ongoing); Janssen Biotech Inc: Consultant (Ongoing), Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Lantheus: Meeting participant/lecturer (Ongoing); Lipella Pharmaceuticals LLC: Scientific Study/Trial (Ongoing); Lynx DX: Consultant (Ongoing); Merck & Co. Inc: Meeting participant/lecturer, Scientific Study/Trial (Ongoing); miR Scientific Inc: Scientific Study/Trial (Ongoing); Myovant Sciences Inc: Consultant (Ongoing), Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Myriad Genetics Inc;: , Meeting participant/lecturer, Scientific Study/Trial (Ongoing), Consultant (Ongoing); Nucleix: Scientific Study/Trial (Ongoing); Pfizer Inc: Consultant (Ongoing), Meeting participant/lecturer, Scientific Study/Trial (Ongoing); Procept-Biorobotic: Meeting participant/lecturer (Ongoing); Promaxo: Consultant (Ongoing); Tolmar Pharmaceuticals Inc: Consultant (Ongoing), Meeting participant/lecturer (Ongoing); Urogen Pharma Inc: Consultant (Ongoing), Meeting participant/lecturer (Ongoing)